Home » Computer & Software » Internet » MMRGlobal Proceeds With $30 Million Patent Licensing Case and Files Three New Federal Appeals
Ihren XING-Kontakten zeigen

MMRGlobal Proceeds With $30 Million Patent Licensing Case and Files Three New Federal Appeals

LOS ANGELES, CA — (Marketwired) — 01/20/15 — (OTCQB: MMRF), through its wholly owned subsidiary, MyMedicalRecords, Inc. (collectively, “MMR”), today announced that following the California Court of Appeal–s finding that the trial court erred in granting Surgery Center Management, LLC–s (“SCM”) motion for summary adjudication, the trial court vacated its order, thereby paving the way for MMR to have the opportunity to proceed with its $30,000,000 patent licensing case against SCM. This ruling represents the second time in this lawsuit that the Court of Appeal interceded with rulings favorable to MMR, highlighting the critical role of appellate courts in ensuring the correct application of law and that justice is ultimately accomplished.

MMR also announced that on January 15, 2015, it filed three notices of appeal to begin the process of challenging recent decisions in the district court pertaining to MyMedicalRecord, Inc.–s patent infringement claims against Allscripts Healthcare Solutions, Inc. and WebMD Health Corp. & WebMD Health Services Group, Inc., amongst others. The appeals will be heard in the United States Court of Appeals for the Federal Circuit (“Federal Circuit”).

The federal appeals focus on the district court–s recent decisions pertaining to claims 8 through 12 of MMR–s U.S. Patent No. 8,301,466 (“–466 patent”) and claims 1 through 3 of MMR–s U.S. Patent No. 8,498,883 (“–883 patent”). The–466 patent contains 15 claims of which only five of those claims are involved in the appeal. The –883 patent contains a total of 28 claims of which only three are involved in the appeal. MMR is committed to pursuing all avenues of review of the lower court decisions. The Federal Circuit is the only appellate-level court with jurisdiction to hear patent case appeals.

MMR–s health information technology patent portfolio which, dating back to filings in 2005, currently includes 13 U.S. patents (with over 300 issued claims), 17 additional pending U.S. patent applications (with over 300 claims), nine foreign patents, including two in Australia, two in Mexico, with others in New Zealand, Singapore, Japan, South Korea, and Canada, and 25 other pending patent applications in foreign countries. The lower court–s decision also does not affect these other patents.

MMR will continue to pursue opportunities to monetize its U.S. patents where appropriate in the burgeoning health information technology marketplace. In the meantime, MMR continues to offer its products and services to enter into license agreements with healthcare professionals including pharmacy chain retailers.

MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user–s account. The Company–s professional offering, , is designed to give physicians– offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId/Specifid vaccine clinical trials for the treatment of B-Cell Non-Hodgkin–s lymphoma. To learn more about MMRGlobal, Inc. visit . View demos and video tutorials of the Company–s products and services at .

All statements in this release that are not strictly historical in nature, whether or not such statement relates directly to Surgery Center Management, LLC, are “forward-looking statements.” Such forward-looking statements are based on MMR–s current assumptions, beliefs and expectations, and involve risks, uncertainties and other factors that may cause MMR–s actual results to be materially different from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words such as “expect,” “plan,” “possibility,” “offer,” “if,” “negotiate,” “when,” “believe,” “will,” “estimate,” “continue,” and similar expressions. Risks, uncertainties, and other factors that could cause or contribute to such differences include, but are not limited to: ongoing and future intellectual property enforcement actions; the ability to successfully litigate or settle claims of patent infringement; MMR–s ability to develop, license and monetize its patent and the additional patents in the portfolio for both MMR–s health IT and biotechnology IP assets; reliance upon the successful operations of its business partners in selling MMR–s products and services, the timing of milestone payments in connection with licensing its IP; MMR–s ability to obtain necessary financing, generate sufficient cash flow, and maintain appropriate indebtedness; and the increasing development of market competition in the area of personal and electronic health records. These factors and others are described in more detail in MMR–s public filings with the Securities and Exchange Commission, including the risks discussed in the “Risk Factors” section in MMR–s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Copies of these reports can be found on MMR–s website () under the heading “Investor Relations.” MMR is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

CONTACT:

Michael Selsman
Public Communications Co.
(310) 922-7033

You must be logged in to post a comment Login


Blogverzeichnis - Blog Verzeichnis bloggerei.de Blog Top Liste - by TopBlogs.de Bloggeramt.de blogoscoop